#1 Clinical Trials Search in Europe

[18F]Meta-Fluorobenzylguanidine

[18F]Meta-Fluorobenzylguanidine, also known as [18F]mFBG, is an innovative imaging agent being studied in clinical trials for the detection of neuroblastoma and pheochromocytoma. This radioactive tracer is used in PET-CT scans to help doctors better visualize and diagnose these rare tumors. The ongoing research aims to compare its effectiveness with current imaging techniques and establish its safety profile.

Table of Contents

What is [18F]META-FLUOROBENZYLGUANIDINE?

[18F]META-FLUOROBENZYLGUANIDINE, also known as [18F]mFBG, is a diagnostic tool used in medical imaging[1]. It is a radioactive tracer that is injected into the body to help doctors see certain types of tumors more clearly. This substance is given as a solution for injection and is used in combination with a special type of imaging called PET-CT (Positron Emission Tomography-Computed Tomography)[2].

It’s important to note that [18F]mFBG has several other names that you might hear doctors or researchers use. These include:

  • Florbenguane (18F)
  • IRP-101
  • 1-(3-(fluoro-18F)benzyl)guanidine

Medical Conditions [18F]mFBG Can Help Diagnose

[18F]mFBG is being studied for its ability to help diagnose two main types of tumors:

  1. Neuroblastoma: This is a type of cancer that develops from immature nerve cells. It most commonly affects children[1].
  2. Pheochromocytoma: This is a rare tumor that develops in the adrenal glands, which are located on top of the kidneys. These tumors can cause the body to produce too many hormones, leading to various symptoms[2].

How [18F]mFBG Works

[18F]mFBG works by targeting specific features of these tumors. When injected into the body, it attaches to something called the norepinephrine transporter, which is found in high levels in neuroblastoma and pheochromocytoma cells[2]. This allows the tumors to “light up” on the PET-CT scan, making them easier for doctors to see and diagnose.

Advantages of [18F]mFBG PET-CT

Researchers are studying [18F]mFBG because it may offer several advantages over current diagnostic methods:

  • Improved detection: It may be better at finding both skeletal lesions (tumors in bones) and soft tissue lesions compared to the current standard method ([123I]mIBG scanning)[1].
  • Faster results: The PET-CT scan with [18F]mFBG can potentially be done more quickly than current methods[1].
  • More detailed images: PET-CT scans generally provide more detailed images than other types of scans, which could help doctors make more accurate diagnoses[2].

Current Clinical Trials

As of now, [18F]mFBG is being studied in clinical trials to determine how well it works compared to current diagnostic methods. Two main studies are ongoing:

  1. A study comparing [18F]mFBG PET-CT to [123I]mIBG scanning in patients with neuroblastoma[1].
  2. A study using [18F]mFBG PET-CT to image pheochromocytoma[2].

These studies aim to determine how accurate [18F]mFBG is in detecting tumors, the best timing for the scans, and how safe it is to use in patients.

Safety Considerations

As with any medical procedure, there are some safety considerations to keep in mind:

  • [18F]mFBG is radioactive, so the amount used is carefully controlled to minimize radiation exposure[1].
  • It cannot be used in pregnant or breastfeeding women[2].
  • Researchers are carefully monitoring for any side effects or adverse reactions in the clinical trials[2].

It’s important to remember that [18F]mFBG is still being studied and is not yet approved for general use. If you or a loved one has been diagnosed with neuroblastoma or pheochromocytoma, talk to your doctor about the best diagnostic options for your specific situation.

Aspect Neuroblastoma Trial Pheochromocytoma Trial
Main Objective Compare [18F]mFBG PET-CT to [123I]mIBG SPECT-CT for skeletal lesion detection Compare [18F]mFBG PET-CT to conventional CT for pheochromocytoma lesion detection
Key Inclusion Criteria Patients with suspected neuroblastoma referred for [123I]mIBG imaging Patients ≥18 years with diagnosed or suspected pheochromocytoma, planned for surgery
Primary Endpoint Number of detected skeletal lesions Number of histologically proven pheochromocytoma lesions detected
Secondary Objectives Soft tissue lesion detection, radiation dose calculation, interobserver agreement Optimal imaging time point, correlation with pathology, radiation dose estimation, safety analysis
Drug Information [18F]meta-fluorobenzylguanidine solution for injection 1-(3-(fluoro-18F)benzyl)guanidine ([18F]mFBG) solution for injection

FAQ

  • What is [18F]Meta-Fluorobenzylguanidine used for in clinical trials? [18F]Meta-Fluorobenzylguanidine is being studied as an imaging agent for detecting neuroblastoma and pheochromocytoma. It is used in PET-CT scans to help visualize these tumors more effectively.
  • How does [18F]mFBG compare to current imaging techniques? Clinical trials are comparing [18F]mFBG PET-CT scans to conventional imaging methods like [123I]mIBG SPECT-CT for neuroblastoma and CT scans for pheochromocytoma. The goal is to determine if [18F]mFBG can detect tumors more accurately.
  • Who can participate in these clinical trials? Participants include patients with suspected or diagnosed neuroblastoma or pheochromocytoma. For the pheochromocytoma study, patients must be 18 years or older and have planned surgery. Specific inclusion and exclusion criteria apply for each trial.
  • What are the potential benefits of using [18F]mFBG? If proven effective, [18F]mFBG could provide more accurate tumor detection, potentially leading to better diagnosis and treatment planning for patients with neuroblastoma and pheochromocytoma.
  • Are there any safety concerns with [18F]mFBG? The clinical trials are assessing the safety of [18F]mFBG by monitoring for adverse events. They are also calculating the radiation dose absorbed by normal organs and tumor lesions to ensure it's within safe limits.

Ongoing Clinical Trials on [18F]Meta-Fluorobenzylguanidine

  • Study Comparing [18F]meta-fluorobenzylguanidine PET-CT and Iodine (123I) Iobenguane Scans for Detecting Neuroblastoma in Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Neuroblastoma: A type of cancer that develops from immature nerve cells, most commonly occurring in children.
  • Pheochromocytoma: A rare tumor that develops in the adrenal glands, which are located on top of the kidneys.
  • PET-CT: Positron Emission Tomography-Computed Tomography, an imaging technique that combines PET and CT scans to provide detailed pictures of the body's structures and functions.
  • SPECT-CT: Single Photon Emission Computed Tomography-Computed Tomography, an imaging technique that combines SPECT and CT scans to provide 3D images of the body.
  • SUV: Standardized Uptake Value, a measure of how much radiotracer is taken up by tissue in PET imaging.
  • Metanefrines: Substances produced when the body breaks down adrenaline and noradrenaline, often elevated in patients with pheochromocytoma.
  • ECOG status: Eastern Cooperative Oncology Group performance status, a scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Norepinephrine transporter: A protein responsible for the uptake of norepinephrine (a type of hormone) into cells.
  • PATLAK imaging: A method used to analyze dynamic PET data to quantify the uptake rate of a tracer in tissue.

References

  1. http://clinicaltrials.eu/trial/study-comparing-18fmeta-fluorobenzylguanidine-pet-ct-and-iodine-123i-iobenguane-scans-for-detecting-neuroblastoma-in-patients/
  2. http://clinicaltrials.eu/trial/study-on-18fmfbg-pet-ct-imaging-for-patients-with-pheochromocytoma/